tbuckley/cabot-search huggingface dataset:
Phase II Study of S-1 Monotherapy with Application of Dose-Adjustment by Creatinine Clearance in Chemonaive Elderly Patients with Advanced Non-Small-Cell Lung Cancer
Authors: T. Kijima, T. Shiroyama, K. Komuta, S. Yamamoto, S. Minami, Y. Ogata, K. Okafuji, S. Ihara, F. Imamura, K. Nishino, T. Hirashima, I. Tachibana, I. Kawase, A. Kumanogoh
Journal: Annals of Oncology (2012)
Vinorelbine is an Active Drug in Desmoid Tumors / Aggressive Fibromatosis: Institut Gustave Roussy Experience
Authors: C. Rahal, A. Cioffi, J. Domont, S. Bonvalot, C. Le Pechoux, L. Vilcot, P. Terrier, F. Fayard, A. Rahal, A. Lecesne
Journal: Annals of Oncology (2012)
Quality of Care for Patients Hospitalized for Heart Failure in China
Authors: Aakriti Gupta, Yuan Yu, Qi Tan, Shuling Liu, Frederick A. Masoudi, Xue Du, Jian Zhang, Harlan M. Krumholz, Jing Li
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Given the emerging heart failure (HF) epidemic in China, monitoring and improving the quality of care for heart failure is a top priority. <h3>Objectives</h3> To assess the quality of HF care provided to inpatients by examining the adherence to quality measures for HF care at the hospital level and to identify factors associated with the quality of care. <h3>Design, Setting, and Participants</h3> In this multicenter, hospital-based, retrospective cross-sectional study in China, medical records of patients hospitalized for HF from January 1, 2015, to December 31, 2015, were analyzed from January 1, 2018, to May 20, 2019. In the first stage, simple random sampling stratified by economic-geographical regions in China was used to generate a list of participating hospitals. In the second stage, 15 538 hospitalizations from the 189 selected hospitals were systematically sampled, and 10 004 HF hospitalizations were included in the final sample. <h3>Main Outcomes and Measures</h3> Adherence to the following 4 core performance measures at the hospital level: (1) left ventricular ejection fraction assessment during hospitalization; (2) evidence-based β-blocker (bisoprolol, carvedilol, or metoprolol succinate) for eligible patients at discharge; (3) angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for eligible patients at discharge; and (4) scheduled follow-up appointment at discharge. At the hospital level, a composite performance score (ranging from 0-1) was also calculated by averaging these measures. <h3>Results</h3> In total, 10 004 hospital admissions for HF at 189 hospitals were included in this study. The median (interquartile range [IQR]) patient age at admission was 73 (65-80) years, and 5117 (51.1%) of the patients were men. Among all hospitals, the median rate of adherence to measure 1 was 66.7% (IQR, 45.5%-80.7%; range, 0%-100%). The rate for adherence to measure 2 was 14.8% (IQR, 0%-37.5%; range, 0%-81.8%), and the rate for measure 3 was 57.1% (IQR, 36.4%-75.0%; range, 0%-100%). For measure 4, the median rate of adherence was 11.5% (IQR, 3.3%-32.8%; range, 0%-96.7%). The median (IQR) composite performance score across all hospitals was 40.0% (26.9%-51.9%), with a range from 2.2% to 85.4%. The median odds ratios of adherence were 2.2 (95% CI, 2.0-2.4) for measure 1, 2.1 (95% CI, 1.8-2.4) for measure 2, 2.4 (95% CI, 2.0-2.9 for measure 3, and 4.8 (95% CI, 3.9-5.8) for measure 4 among hospitals. <h3>Conclusions and Relevance</h3> The findings of this study suggest that quality of care for patients with HF in China may be substandard, and there is wide heterogeneity in the quality of care for HF among hospitals. The findings also suggest the need for a national strategy to improve and standardize the quality of HF care in China.
Prognostic Factors in Recurrent Small-Cell Lung Carcinoma
Authors: M. Morise, T. Mizutani, T. Oguri, N. Imai, T. Hase, Y. Shindo, Y. Inukai, S. Ito, N. Hashimoto, M. Sato, M. Kondo, Y. Hasegawa
Journal: Annals of Oncology (2012)
The Quality of End-of-Life Care among ICU versus Ward Decedents
Authors: Joshua A. Rolnick, Mary Ersek, Melissa W. Wachterman, Scott D. Halpern
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Rationale: Admissions to ICUs are common during terminal hospitalizations, but little is known about how ICU care affects the end-of-life experience for patients dying in hospitals and their families.Objectives: We measured the association between ICU care during terminal hospitalization and family ratings of end-of-life care for patients who died in 106 Veterans Affairs hospitals from 2010 to 2016.Methods: Patients were divided into four categories: no-ICU care, ICU-only care, mixed care (died outside ICU), and mixed care (died in ICU). Multivariable linear probability models were adjusted for patient and hospital characteristics. Patients receiving mixed care were also analyzed based on percentage of time in ICU.Measurements and Main Results: Of 57,550 decedents, 28,062 (48.8%) had a survey completed by a family member or close contact. In adjusted models, ICU-only care was associated with more frequent optimal ratings than no-ICU care, including overall excellent care (56.6% vs. 48.1%; P < 0.001), care consistent with preferences (78.7% vs. 72.4%; P < 0.001), and having pain controlled (51.3% vs. 46.7%; P < 0.001). Among patients with mixed care, increasing ICU time was associated with higher ratings on these same measures (all P < 0.001 for comparisons of those spending >75% time in ICU vs. ≤25% time).Conclusions: Among hospital decedents, ICU care was associated with higher family ratings of quality of end-of-life care than ward care. Reducing ICU use among hospital decedents may not improve end-of-life quality, and efforts to understand how ICU care improves end-of-life quality could help provide better care outside ICUs.
Interventions and Operations 5 Years After Bariatric Surgery in a Cohort From the US National Patient-Centered Clinical Research Network Bariatric Study
Authors: Anita Courcoulas, R. Yates Coley, Jeanne M. Clark, Corrigan L. McBride, Elizabeth Cirelli, Kathleen McTigue, David Arterburn, Karen J. Coleman, Robert Wellman, Jane Anau, Sengwee Toh, Cheri D. Janning, Andrea J. Cook, Neely Williams, Jessica L. Sturtevant, Casie Horgan, Ali Tavakkoli
Journal: JAMA Surgery (2020)

Additional data comparing longer-term problems associated with various bariatric surgical procedures are needed for shared decision-making.To compare the risks of intervention, operation, endoscopy, hospitalization, and mortality up to 5 years after 2 bariatric surgical procedures.Adults who underwent Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) between January 1, 2005, and September 30, 2015, within the National Patient-Centered Clinical Research Network. Data from 33 560 adults at 10 centers within 4 clinical data research networks were included in this cohort study. Information was extracted from electronic health records using a common data model and linked to insurance claims and mortality indices. Analyses were conducted from January 2018 through October 2019.Bariatric surgical procedures.The primary outcome was time until operation or intervention. Secondary outcomes included endoscopy, hospitalization, and mortality rates.Of 33 560 adults, 18 056 (54%) underwent RYGB, and 15 504 (46%) underwent SG. The median (interquartile range) follow-up for operation or intervention was 3.4 (1.6-5.0) years for RYGB and 2.2 (0.9-3.6) years for SG. The overall mean (SD) patient age was 45.0 (11.5) years, and the overall mean (SD) patient body mass index was 49.1 (7.9). The cohort was composed predominantly of women (80%) and white individuals (66%), with 26% of Hispanic ethnicity. Operation or intervention was less likely for SG than for RYGB (hazard ratio, 0.72; 95% CI, 0.65-0.79; P < .001). The estimated, adjusted cumulative incidence rates of operation or intervention at 5 years were 8.94% (95% CI, 8.23%-9.65%) for SG and 12.27% (95% CI, 11.49%-13.05%) for RYGB. Hospitalization was less likely for SG than for RYGB (hazard ratio, 0.82; 95% CI, 0.78-0.87; P < .001), and the 5-year adjusted cumulative incidence rates were 32.79% (95% CI, 31.62%-33.94%) for SG and 38.33% (95% CI, 37.17%-39.46%) for RYGB. Endoscopy was less likely for SG than for RYGB (hazard ratio, 0.47; 95% CI, 0.43-0.52; P < .001), and the adjusted cumulative incidence rates at 5 years were 7.80% (95% CI, 7.15%-8.43%) for SG and 15.83% (95% CI, 14.94%-16.71%) for RYGB. There were no differences in all-cause mortality between SG and RYGB.Interventions, operations, and hospitalizations were relatively common after bariatric surgical procedures and were more often associated with RYGB than SG.ClinicalTrials.gov identifier: NCT02741674.
Personalizing<i>KRAS</i>-Mutant Allele–Specific Therapies
Authors: Chiara Falcomatà, Günter Schneider, Dieter Saur
Journal: Cancer Discovery (2020)

KRASG12R mutations occur almost exclusively in pancreatic ductal adenocarcinoma. The results of a study that reveals specific differences in KRAS downstream signaling and metabolic rewiring of pancreatic cancer cells harboring KRASG12R mutations promise to improve our possibilities to better stratify patients for individualized therapies.See related article by Hobbs et al., p. 104.
HDJ-2 is an important target of farnesyltransferase inhibitor, R115777, induced radiosensitization
Authors: Chun-Chieh Wang, Paul Mischel, William McBride
Journal: Cancer Research (2005)

1655  Farnesylation is an important posttranslational modification of proteins that leads to changes in protein trafficking and protein-protein interactions. Blocking protein farnesylation was thought to inhibit ras and its downstream signal transduction pathways, and several farnesyltransferase inhibitors (FTIs), such as R115777, demonstrate anticancer activity as single agents and in combination with standard chemotherapy or irradiation. However, the critical target of FTIs leading to its anti-tumor activity is still controversial. In this study, we investigated the potential role of a farnesylated protein, HDJ-2, in FTI-induced radiosensitization. HDJ-2 is a cochaperone that can regulate other heat shock proteins. Unfarnesylated HDJ-2 could be detected within 30 min of treatment of two GBM cell lines, U251 and SF763 with 10nM R1155777 rising to 50% by 6 hours. Interestingly, R115777 also radiosensitized these cell lines within 6 hours. The survival fraction at 2Gy, determined by the clonogenic assay, decreased about 15% for both cell lines. Overexpression of geranylgeranylated HDJ-2 increased radioresistance of SF763 cells and neutralized the radiosensitization effect of R115777. In addition, suppression of HDJ-2 expression by RNA inference decreased the radioresistance of SF763 cells. Although radiation did not change expression of HDJ-2 mRNA and protein (by real-time RT-PCR and Western blot), confocal microscopy revealed that HDJ-2 relocalized to peri-nuclear and intra-nuclear regions after irradiation and that cells undergoing mitotic catastrophe had high concentrated HDJ-2 within their micronuclei. Examination of nuclear staining of HDJ-2 by flow cytometer confirmed accumulation of HDJ-2 in nuclei after irradiation in both SF763 and U251 cells. These results suggest that HDJ-2 could be involved in the repair of radiation nuclear damage and play an important role in FTI-induced radiosensitization.
The Significance of Ephrin Receptor A4 (Epha4) Expression in Primary Pulmonary Neoplasms
Authors: N.G. Tsoukalas, I. Kostakis, M. Tolia, A. Tzovaras, C. Giaginis, I. Sfiniadakis, K. Tsolakis, A. Karameris, E. Patsouris, S. Theocharis
Journal: Annals of Oncology (2012)
Health-Related Quality of Life (QOL) in Metastatic Breast Cancer Patients Treated With Everolimus and Exemestane Versus Exemestane Monotherapy
Authors: H. Burris, J.T. Beck, H. Rugo, J. Baselga, F. Lebrun, T. Taran, L. Bennett, J. Ricci, T. Sahmoud, G.N. Hortobagyi
Journal: Annals of Oncology (2012)
Cyclin D1, EGFR and AKT/MTOR Signalling in Localized Laryngeal Squamous Cell Carcinoma
Authors: D. Dionysopoulos, K. Pavlakis, V. Kotoula, E. Fountzilas, K. Markou, I. Karasmanis, N. Angouridakis, A. Nikolaou, K.T. Kalogeras, G. Fountzilas
Journal: Annals of Oncology (2012)
Results of a First-In-Human Phase I Study of the Alk Inhibitor LDK378 in Advanced Solid Tumors
Authors: A.T. Shaw, D.R. Camidge, E. Felip, S. Sharma, D.S.W. Tan, D. Kim, T. De Pas, J.F. Vansteenkiste, A. Santoro, G. Liu, M. Goldwasser, D. Dai, A.L. Boral, R. Mehra
Journal: Annals of Oncology (2012)
Gclust: A Parallel Clustering Tool for Microbial Genomic Data
Authors: Ruilin Li, Xiaoyu He, Chuangchuang Dai, Haidong Zhu, Xianyu Lang, Wei Chen, Xiaodong Li, Dan Zhao, Yu Zhang, Xinyin Han, Tie Niu, Yi Zhao, Rongqiang Cao, Rong He, Zhonghua Lu, Xuebin Chi, Weizhong Li, Beifang Niu
Journal: Genomics Proteomics & Bioinformatics (2019)

The accelerating growth of the public microbial genomic data imposes substantial burden on the research community that uses such resources. Building databases for non-redundant reference sequences from massive microbial genomic data based on clustering analysis is essential. However, existing clustering algorithms perform poorly on long genomic sequences. In this article, we present Gclust, a parallel program for clustering complete or draft genomic sequences, where clustering is accelerated with a novel parallelization strategy and a fast sequence comparison algorithm using sparse suffix arrays (SSAs). Moreover, genome identity measures between two sequences are calculated based on their maximal exact matches (MEMs). In this paper, we demonstrate the high speed and clustering quality of Gclust by examining four genome sequence datasets. Gclust is freely available for non-commercial use at https://github.com/niu-lab/gclust. We also introduce a web server for clustering user-uploaded genomes at http://niulab.scgrid.cn/gclust.
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland
Authors: C.M. Panje, J.E. Lupatsch, M. Barbier, E. Pardo, M. Lorez, K.J. Dedes, D.M. Aebersold, L. Plasswilm, O. Gautschi, M. Schwenkglenks
Journal: Annals of Oncology (2020)
Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
Authors: João Manuel Santos, Camilla Heiniö, Victor Cervera-Carrascon, Dafne C A Quixabeira, Mikko Siurala, Riikka Havunen, Ralf Butzow, Sadia Zafar, Tanja de Gruijl, Heini Lassus, Anna Kanerva, Akseli Hemminki
Journal: Journal for ImmunoTherapy of Cancer (2020)

Ovarian cancers often contain significant numbers of tumor-infiltrating lymphocytes (TILs) that can be readily harnessed for adoptive T-cell therapy (ACT). However, the immunosuppressive ovarian tumor microenvironment and lack of tumor reactivity in TILs can limit the effectiveness of the therapy. We hypothesized that by using an oncolytic adenovirus (Ad5/3-E2F-D24-hTNFa-IRES-hIL2; TILT-123) to deliver tumor necrosis factor alpha (TNFa) and interleukin-2 (IL-2), we could counteract immunosuppression, and enhance antitumor TIL responses in ovarian cancer (OVCA). We established ex vivo tumor cultures freshly derived from patients with advanced OVCA and evaluated the effects of Ad5/3-E2F-D24-hTNFa-IRES-hIL2 or Ad5/3-E2F-D24 (the control virus without TNFa and IL-2) on TILs, cytokine response and tumor viability. Tumor reactivity was assessed by determining interferon gamma (IFNg) response of clinically relevant TILs towards autologous T-cell-depleted ex vivo tumor cultures pretreated with or without the aforementioned oncolytic adenoviruses. Treatment of ex vivo tumor cultures with Ad5/3-E2F-D24-hTNFa-IRES-hIL2 caused a substantial rise in proinflammatory signals: increased secretion of IFNg, CXCL10, TNFa and IL-2, and concomitant activation of CD4+ and CD8+ TILs. Potent tumor reactivity was seen, as clinically relevant TIL secreted high levels of IFNg in response to autologous T-cell-depleted ovarian ex vivo tumor cultures treated with Ad5/3-E2F-D24-hTNFa-IRES-hIL2. This phenomenon was independent of PD-L1 expression in tumor cells, a factor that determined the variability of IFNg responses seen in different patient samples. Overall, oncolytic adenovirus Ad5/3-E2F-D24-hTNFa-IRES-hIL2 was able to rewire the ovarian tumor microenvironment to accommodate heightened antitumor TIL reactivity. Such effects may improve the clinical effectiveness of ACT with TILs in patients with advanced OVCA.
Reduced seroprevalence against vaccine preventable diseases (VPDs) in adult patients with cancer: necessity of routine vaccination as part of the therapeutic concept
Authors: A. Guzek, A.S. Berghoff, J. Jasinska, E. Garner-Spitzer, A. Wagner, K. Stiasny, H. Holzmann, M. Kundi, C. Zielinski, U. Wiedermann
Journal: Annals of Oncology (2020)
P1.04 Clinical Diagnostic Implementation of an Innovative Cancer Care Model Based on Comprehensive Molecular Profiling of Tumour-Normal Pairs
Authors: K. Kaur, S. Henderson, A. Cutts, E. Domingo, J. Woods, C. Motley, B. Dougherty, M. Middleton, B. Hassan, Y. Wang, E. Beasley, M. Naley, A. Schuh, I. Tomlinson, J. Taylor
Journal: Annals of Oncology (2012)
Optimal Asthma Control: Time for a New Target
Authors: Richard Beasley, Irene Braithwaite, Alex Semprini, Ciléin Kearns, Mark Weatherall, Ian D. Pavord
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Section:ChooseTop of pageAbstract <<Are Total Control or Well...Factors Contributing to S...Disparity between Patient...Population-based Prescrib...Symptom Control and Reduc...ConclusionsPanel: The EvidenceReferencesCITING ARTICLES
Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study
Authors: Ying-Xuan Chen, Qin-Yan Gao, Tian-Hui Zou, Bang-Mao Wang, Si-De Liu, Jian-Qiu Sheng, Jian-Lin Ren, Xiao-Ping Zou, Zhan-Ju Liu, Yan-Yan Song, Bing Xiao, Xiao-Min Sun, Xiao-Tan Dou, Hai-Long Cao, Xiao-Ning Yang, Na Li, Qian Kang, Wei Zhu, Hong-Zhi Xu, Hui-Min Chen, Xiao-Chuang Cao, Jing-Yuan Fang
Journal: The Lancet. Gastroenterology & hepatology (2020)
Post-Marketing Clinical Study of Pemetrexed (PEM) Combined with Carboplatin (CBDCA) Followed by Maintenance PEM in Patients with Non-Squamous Non-Small Cell Lung Cancer (non-sq NSCLC): 18-Month Follow-up Data
Authors: T. Kumagai, F. Imamura, S. Atagi, K. Takeda, R. Sekiguchi, S. Enatsu, K. Nakagawa, T. Tamura
Journal: Annals of Oncology (2012)
Cancer and Lung Transplantation
Authors: D. Pérez Callejo, R. Laporta, E. Almagro Casado, M. Palka, A. Ruiz-Valdepeñas, B. Cantos, C. Maximiano, M. Méndez García, P. Ussetti, M. Provencio Pulla
Journal: Annals of Oncology (2012)
Randomized Phase III Study Comparing Etoposide and Cisplatin (EP) with Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Radiotherapy (EP/AHTRT) for the Treatment of Limited-Stage Small-Cell Lung Cancer (LD-SCLC): JCOG0202
Authors: T. Hida, K. Kubota, S. Ishikura, T. Shibata, M. Nishio, M. Kawahara, A. Yokoyama, F. Imamura, K. Takeda, S. Negoro, H. Okamoto, N. Yamamoto, T. Shinkai, N. Saijo, T. Tamura
Journal: Annals of Oncology (2012)
Quality Indicators and Non Small Cell Lung Cancer Integrated Care Pathway: a Single-Center Experience
Authors: J. Menis, A. Follador, F. Valent, C. Rossetto, M. Gaiardo, L. Gurrieri, E. Lugatti, S. Pizzolitto, V. Tozzi, G. Fasola
Journal: Annals of Oncology (2012)
Phase II Study of Combination Chemotherapy with Oral S-1 and Oxaliplatin (SOX) in Patients with Mucinous Adenocarcinoma of the Ovary
Authors: S. Nishio, M. Shimada, T. Kamura, K. Ishitani, K. Ochiai, N. Takeshima, Y. Yokoyama, H. Furumoto, T. Sugiyama, J. Kigawa
Journal: Annals of Oncology (2012)
Phase II Clinical and Pharmacokinetic (PK) Trial of Zalypsis (Z) in Patients with Urothelial Carcinoma (UC) Progressing after a First-Line Platinum-Based Regimen
Authors: J. Carles, J. Bellmunt, P. Maroto, A. Font, R. Morales-Barrera, C. Suarez, C. Martin Lorente, O. Etxaniz, L. Capdevila, D.E. Castellano
Journal: Annals of Oncology (2012)
The Clinical Significance of the Serum Cross-Linked N-Telopeptide of Type I Collagen as a Prognostic Marker for Non-Small-Cell Lung Cancer
Authors: T. Shiroyama, M. Tamiya, T. Hirashima, S. Morita, O. Morimura, K. Okafuji, N. Morishita, H. Suzuki, N. Okamoto, M. Kobayashi, T. Hirashima, I. Kawase
Journal: Annals of Oncology (2012)
A Prospective, Molecular Epidemiological Study of EGFR Mutations in Asian Patients (PTS) with Advanced Non-Small-Cell Lung Cancer with Adenocarcinoma Histology (PIONEER) – China Subset Analysis
Authors: Y. Shi, S. Zhang, M. Wang, S. Yang, N. Li, G. Wu, W. Liu, G. Liao, K. Cai, L. Chen
Journal: Annals of Oncology (2012)
P-0109 Survival Analysis of Maintenance Therapy with Capecitabine in Patients with Resected Pancreatic Adenocarcinoma after Adjuvant Therapy, a Retrospective Cohort Study
Authors: Xuezhong Yang, Christina Wu, Jimmy Hwang, Madeeha Akram, Benjamin Weinberg, Michael Pishvaian, Dai Luu, Tanios Bekaii-Saab, Aiwu He, John Marshall
Journal: Annals of Oncology (2012)
Neoadjuvant (NACT) and Adjuvant Chemotherapy (ACT) for Muscle-Invasive Bladder Cancer: A Population-Based Outcomes Study
Authors: C.M. Booth, D.R. Siemens, G. Li, Y. Peng, I.F. Tannock, D.M. Berman, W. Kong, W.J. Mackillop
Journal: Annals of Oncology (2012)
Comparison of Efficacy in Chemotherapy for Large-Cell Neuroendocrine Carcinoma of the Lung and Small-Cell Lung Cancer
Authors: H. Ishida, Y. Ohki, Y. Murata, K. Ishida, S. Kusumoto, T. Sugiyama, T. Shirai, M. Nakashima, T. Yamaoka, K. Okuda, T. Ohnishi, T. Ohmori, T. Hirose
Journal: Annals of Oncology (2012)
P-0016 Brachytherapy of Inoperable Oesophageal Carcinoma
Authors: Igor Richter, Jiri Petera, Josef Dvorak, Linda Kasaova, Jana Bedrosova, Milan Zouhar, Petr Paluska, Igor Sirak, Zdenek Zoul, Milan Vosmik
Journal: Annals of Oncology (2012)
Effects of SRC Inhibition on Survival, Migration and Invasion of Human Breast Cancer Cells Resistant to Lapatinib
Authors: L. Nappi, L. Formisano, R. Rosa, V. Damiano, T. Gelardi, C. D'Amato, V. D'Amato, R. Marciano, A.P. De Maio, R. Bianco
Journal: Annals of Oncology (2012)
National Institutes of Health Pathways to Prevention Workshop: Achieving Health Equity in Preventive Services
Authors: Timothy S. Carey, Betty Bekemeier, Doug Campos-Outcalt, Susan Koch-Weser, Sandra Millon-Underwood, Steven Teutsch
Journal: Annals of Internal Medicine (2020)

Expert groups, including the U.S. Preventive Services Task Force (USPSTF), recommend a range of clinical preventive services for persons at average risk for disease. Use of these services often is substantially lower among racial and ethnic minority groups, rural residents, and persons of lower socioeconomic status. On 19 and 20 June 2019, the National Institutes of Health (NIH) convened the Pathways to Prevention Workshop: Achieving Health Equity in Preventive Services to assess the available evidence on disparities in the use of 10 USPSTF-recommended clinical preventive services for cancer, heart disease, and diabetes. The workshop was cosponsored by the NIH Office of Disease Prevention; National Institute on Minority Health and Health Disparities; National Cancer Institute; National Heart, Lung, and Blood Institute; and National Institute of Diabetes and Digestive and Kidney Diseases. A multidisciplinary working group developed the agenda, and an Evidence-based Practice Center prepared the evidence report. During the workshop, invited experts considered the evidence, with discussion among attendees. After weighing evidence from the review, presentations, and public comments, an independent panel prepared a draft report that was posted for public comment. This final report summarizes the panel's findings, identifying current gaps in knowledge. The panel made 26 recommendations for new research and methods development to improve implementation of proven services to reduce disparities in preventable conditions.